Research OnlyCognitive Enhancement

Dihexa

Also known as: PNB-0408, N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide

An experimental peptide developed at Washington State University from the angiotensin IV system. It has generated interest because of animal research suggesting it is extremely potent at promoting new synapse formation, but it has no human clinical trials.

How it works

Dihexa activates the hepatocyte growth factor (HGF) and c-Met receptor system, which is involved in cell growth, repair, and the formation of new brain connections. Lab studies report it may be up to 10 million times more potent than BDNF at promoting new synapse formation, though this is only demonstrated in cell and animal studies.

Common uses

Side effects

Key research

Safety notes

  • Zero human clinical trials have been completed for Dihexa itself
  • Not FDA-approved for any indication
  • No established dosing guidelines for humans
  • The pro-drug fosgonimeton is the version being developed through proper clinical channels
  • Extreme caution is warranted due to its potent growth factor activity

Too many clinics, not enough clarity?

We don't sell peptides. Tell us your goals and we'll connect you with a vetted provider who can figure out what actually makes sense for you.

See what's right for you

Explore other peptides